Small- And Mid-Cap Biotech Picks For 2021
Small- And Mid-Cap Biotech Picks For 2021 and holdovers from 2020.
How To Capitalize On What Could Be “The Best Decade, Ever, For The Stock Market”
Now, as 2021 begins, the author of today’s article believes that the “next decade could easily be the best decade, ever, for the stock market as post-war euphoria and easy money policy couple with multiple hypergrowth technological breakthroughs to rapidly unlock tremendous and widespread economic value.”
Why Individual Stock Selection Will Be Key For Biotech Investors In 2021 – And RBC’s 15 Top Ideas
When it comes to biotech investing in 2021, healthcare stock analysts at RBC advised in a recent report that “Many pandemic-related influences are setting up the sector for outperformance but several factors could still work against the group, making individual stock selection a key priority…”
4 Biotech Penny Stocks To Watch Right Now – Including A Truly Psychedelic Stock
“Since we know small-cap stocks are hot and biotech stocks are as well, it might make sense to follow some smaller biotech penny stocks this month,”
1 Buy And 1 Sell To Prepare Your Portfolio For The Precision Medicine Mega Trend
One-size-fits-all drugs are giving way to precision medicine, which the author of today’s article expects will come to dominate the health care marketplace in the next three to five years.
Promising Test Results For Its Cancer Drugs Just Launched This Small Biotech To A Record High
On Monday, the small biotech stock highlighted in today’s article hit a record high, skyrocketing 95.1%. The catalyst?
The Hype And The Data Behind This Breast Cancer Stock’s Massive Surge
The small-cap biotech featured in today’s article has been on a wild trading ride in recent days, having surged 1,600% in two days on enthusiasm for its immunotherapy treatment for breast cancer, clinical trial results for which demonstrate 0% recurrence of the disease at a median of five years in patients who received the treatment following surgery and Herceptin treatment.
5 Aggressive Tech Plays Under $10
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential,” declares the author of today’s… Read More »5 Aggressive Tech Plays Under $10
These Biotechs Are Awaiting FDA Rulings In December
November saw the FDA grant its first emergency use approval for an at-home, self-collected nasal swab test for COVID-19 and approve the first drugs for… Read More »These Biotechs Are Awaiting FDA Rulings In December
This Under-The-Radar Biotech’s Unique Approach To Drug Development Could Supercharge Your Portfolio
With potential COVID-19 vaccines and therapeutics garnering most of the attention this year in the biotech space, the biotech stock featured in today’s article, which has “a unique approach to the business of drug development” for genetic diseases, has been flying under the radar.